1. Home
  2. DAWN vs NCLH Comparison

DAWN vs NCLH Comparison

Compare DAWN & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Day One Biopharmaceuticals Inc.

DAWN

Day One Biopharmaceuticals Inc.

HOLD

Current Price

$9.60

Market Cap

908.7M

Sector

Health Care

ML Signal

HOLD

Logo Norwegian Cruise Line Holdings Ltd.

NCLH

Norwegian Cruise Line Holdings Ltd.

HOLD

Current Price

$24.44

Market Cap

10.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAWN
NCLH
Founded
2018
1966
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
908.7M
10.7B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DAWN
NCLH
Price
$9.60
$24.44
Analyst Decision
Strong Buy
Buy
Analyst Count
9
18
Target Price
$26.56
$28.11
AVG Volume (30 Days)
2.7M
16.5M
Earning Date
02-24-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.76
EPS
N/A
1.40
Revenue
$133,672,000.00
$9,692,558,000.00
Revenue This Year
$15.51
$6.85
Revenue Next Year
$49.99
$10.26
P/E Ratio
N/A
$17.03
Revenue Growth
31.11
3.59
52 Week Low
$5.64
$14.21
52 Week High
$13.53
$29.29

Technical Indicators

Market Signals
Indicator
DAWN
NCLH
Relative Strength Index (RSI) 57.24 70.89
Support Level $8.35 $21.96
Resistance Level $9.59 $24.32
Average True Range (ATR) 0.58 0.86
MACD -0.04 0.13
Stochastic Oscillator 58.35 99.83

Price Performance

Historical Comparison
DAWN
NCLH

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About NCLH Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.

Share on Social Networks: